Condition
Peripheral T-cell Lymphomas
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (2)
P 2 (2)
Trial Status
Completed2
Terminated1
Recruiting1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03922724Phase 2RecruitingPrimary
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
NCT02520219Phase 2UnknownPrimary
Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
NCT00453427Phase 1CompletedPrimary
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
NCT00704691Early Phase 1TerminatedPrimary
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
NCT00374699Phase 1CompletedPrimary
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas
Showing all 5 trials